Supernus Pharmaceuticals Inc SUPN shares are trading lower by $0.80 at $23.89 in Tuesday's session.
The report of positive results from Phase IIb Trial of SPN-812 in children with ADHD meeting the primary endpoint with statistically significant reduction in ADHD symptoms did provide a temporary boost to the issue.
However, some investors have decided to "sell the news" as opposed to buying into it.
Following a sharply higher open ($26.16 vs. Monday's close of $24.89), it went only $0.03 higher to $26.19 before reversing course.
The ensuing decline took the issue to $22.51 before staging a rebound back to the $24 area. That low coincides with its September 15 low of $22.55.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
